This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune disease KYV-101 is a fully human anti-CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif., June 20, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patientcentered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from aut ...

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L Treatment Unique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are Managed ALPHA3 Expected to ...

PONTE VEDRA BEACH, Fla. and PARSIPPANY, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- AVIS, one of the world's best known car rental brands, has today announced a multi-year extension of its partnership as the Official Rental Car Company of the PGA TOUR, PGA TOUR Champions and Korn Ferry Tour. The agreement, through 2028, will continue to provide rental vehicles for players, caddies, employees and fans at PGA TOUR-sanctioned events worldwide. AVIS has been an Official Marketing Partner and the preferred rental ca ...

Dublin, June 17, 2024 (GLOBE NEWSWIRE) -- The "Avis Budget Group (Avis) - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering. The report provides comprehensive information and insights into Avis' tech activities, including its digital transformation strategies and innovation programs. Avis offers car sharing as well as car and truck rental services to customers across the world. The company conducts its operations under several brand names, including Avis, ...

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient administration was allowed and found to be feasible Currently no FDA-approved CAR-T treatments for WM Data presented at the European Hematology Association 2024 Hybrid Congress WORCESTER, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Mustang Bi ...

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral presentation includes upda ...

Thicha Satapitanon/iStock via Getty Images Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been able to advance a few CAR-T products in its pipeline. The reason why I believe that it is good to focus on this biotech next is because it is gearing up to report results from two early-stage studies, which could possibly boost shareholder value. The first candidate of which is known as cema-cel [formerly ALLO-501A] that is being advanced for the treatment of patients with relapsed/refractory chronic lymphocytic le ...

Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption Kyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritis EMERYVILLE, Calif., June 10, 2024 /PRNewswire/ -- K ...

Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is be ...

PARSIPPANY, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) (the "Company") announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the "Issuer"), priced a private offering of €200 million aggregate principal amount of additional 7.25% Senior Notes due 2030 (the "Notes"). The Notes will be issued as additional notes under the Indenture, dated as of July 13, 2023, pursuant to which the Issuer previously issued €400 million aggregate principal amount of 7.25% Sen ...